Production / Operations Routine +

QScreen AI Reports Internal Validation Results for Correctional Intake Platform: 100% Sensitivity on Suicide Risk and Withdrawal Detection Across 65 Calibrated Clinical Scenarios

QScreen AI Validates Correctional Tech Amid Capital Constraints

By The Northwire Desk — AI Analysis May 04, 2026 · 07:04 QAI · 0.04 QScreen AI Inc.

Executive Summary

Latest Validation Results (May 4, 2026): QScreen AI released internal validation results for its correctional intake platform. The system demonstrated 100% sensitivity and specificity on suicide risk, withdrawal detection, and camera fitness clearance across 65 clinical scenarios.
Commercial Pathway: The company is transitioning to a 60-day live pilot program. Success against five pre-defined criteria triggers a 12-month SaaS agreement.
Platform Capabilities: Uses standard laptops/cameras without specialized hardware. Administers nine validated clinical instruments (CIWA-Ar, COWS, etc.) in under seven minutes.
Historical Context: This follows the April 27 announcement of platform completion and active commercial outreach to US Correctional Health, DoD, and Rail sectors. The April 29 news added a strategic advisor from Union Pacific for rail expansion.
Financing History: A non-brokered private placement in February 2026 raised up to C$500,000 at C$0.05 per unit (10M units max). Proceeds were designated for pilot discussions and working capital.

Material Impact

Validation Credibility: The "internal validation" claim is significant but carries risk. While 100% sensitivity on suicide risk is a strong metric, internal testing lacks the peer-review scrutiny of external clinical trials required by federal agencies (DoD/Correctional).
Capital Sufficiency Risk: The February financing raised only C$500,000. This amount is disproportionately small for scaling commercialization across North America (4,800 correctional facilities, 130,000 rail workers, 4,800 military sites).
Revenue Conversion Uncertainty: The news states the pilot converts to revenue upon meeting criteria. There is no guarantee of conversion. The company remains pre-revenue with a high burn rate relative to its cash on hand.
Market Expectation: The market likely anticipated validation results following the April "Platform Complete" announcement. The stock price has not surged significantly post-validation (trading near $0.04 vs $0.09 peak in Nov 2025), suggesting skepticism regarding execution or capital needs.
Auditor Change: The change from Kreston GTA LLP to Bassi & Karimjee LLP on April 13, 2026, is noted without disagreement, but frequent auditor changes in small-cap tech firms often warrant scrutiny for governance issues.

QAI · Price

Company Overview

Company: QScreen AI Inc. (CSE listed).
Flagship Project: QAI Physiological AI Clinical Platform.
Technology: Uses standard camera data to monitor physiological signals (PERCLOS, blink rate) to identify substance impairment in real time without blood/urine samples.
Target Markets: US Correctional Health (~4,800 facilities), National Defence/DoD (~4,800 sites), Rail/Transportation (~130,000 workers).
Intellectual Property: Holds a granted US patent on physiological impairment detection and filed a provisional patent for quantum-inspired optimization in February 2026.
Operational Track Record: Claims over 720,000 real-world scans processed across global deployments.

More from QScreen AI Inc.